FINOVATIS committed to the COVID-19 fight

Partager cette page

Mars 2020

Since 2015 Finovatis has been involved in the IMI-funded ZAPI (Zoonoses Anticipation and Preparedness Initiative) project, aiming to enable swift response to major new infectious disease threats in Europe and throughout the world.


For 5 years the ZAPI has been designing new manufacturing processes (up to large scale) for delivering effective prophylactic and therapeutic solutions (vaccines, antibodies/antibody-like molecules) against (re-)emerging zoonotic diseases with pandemic potential within a few months after the occurrence of first cases. The 3 viruses which were used as models to design this methodology are Middle East respiratory syndrome coronavirus (MERS-CoV), Schmallenberg virus, and Rift Valley Fever. MERS-CoV is genetically related to SARS-CoV-2, the virus that causes the COVID-19.


Several ZAPI outcomes based on the MERS-CoV model can be directly applied to SARS-CoV-2 ().

Finovatis is also involved in the recently H2020-funded MANCO project, building on the outstanding results from the ZAPI project and contributing to the rapid international response against COVID-19, through preclinical and clinical evaluation of monoclonal antibodies against 2019-nCoV.


Retrouvez toutes nos coordonnées sur notre page contact



Estelle-VINCENT_formatcarre.png - 58,43 kB 

Estelle VINCENT  

Project Management Consultant, Finovatis